Inflammatory and cell death pathways in brain and peripheral blood in Parkinson’s disease

CNS and Neurological Disorders - Drug Targets

Volumn 14, Issue 3, 2015, Pages 313-324

  Macchi, Beatrice ^a   Paola, Rosanna Di ^b   Marino Merlo, Francesca ^c   Felice, Maria Rosa ^c   Cuzzocrea, Salvatore ^c,d   Mastino, Antonio ^c,d  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c UNIVERSITY OF MESSINA   (Italy)

^d INSTITUTE OF TRANSLATIONAL PHARMACOLOGY   (Italy)

Author keywords

Apoptosis; Autophagy; Inflammation; Oxidative stress; Parkinson s disease; Target therapy

Indexed keywords

ALPHA SYNUCLEIN; CALCIUM; CASPASE 3; CASPASE 8; CASPASE 9; CYTOKINE; DOPAMINE; FAS ASSOCIATED DEATH DOMAIN PROTEIN; LEUCINE RICH REPEAT KINASE 2; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PROSTAGLANDIN E2; PUMA PROTEIN; REACTIVE OXYGEN METABOLITE; TYROSINE 3 MONOOXYGENASE; UBIQUITIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; AUTOPHAGY; BLOOD; BRAIN; BRAIN FUNCTION; CELL DEATH; CELLULAR STRESS RESPONSE; HUMAN; IMMUNOREACTIVITY; INFLAMMATION; MICROGLIA; MITOPHAGY; MONONUCLEAR CELL; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PROTEIN ASSEMBLY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; IMMUNOMODULATION; METABOLISM; PHYSIOLOGY;

ANIMALS; BRAIN; CELL DEATH; HUMANS; NEUROIMMUNOMODULATION; PARKINSON DISEASE;

EID: 84929250412     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/1871527314666150225124928     Document Type: Article

References (128)

1. Toulouse A, Sullivan AM. Progress in Parkinson's disease-where do we stand? Prog Neurobiol 2008; 85: 376-92.
2. Wirdefeldt K, Adami HO, Cole P, Trichopoulos D, Mandel J. Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur J Epidemiol 2011; 26 Suppl 1: S1-58.
3. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Influence of strict, intermediate, and broad diagnostic criteria on the age- and sex-specific incidence of Parkinson's disease. Mov Disord 2000; 15: 819-25.
4. Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J. Are men at greater risk for Parkinson's disease than women? J Neurol Neurosurg Psychiatry 2004; 75: 637-9.
5. Taylor KS, Cook JA, Counsell CE. Heterogeneity in male to female risk for Parkinson's disease. J Neurol Neurosurg Psychiatry 2007; 78: 905-6.
6. Baldereschi M, Di Carlo A, Rocca WA, et al. Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology 2000; 55: 1358-63.
7. Ishihara LS, Cheesbrough A, Brayne C, Schrag A. Estimated life expectancy of Parkinson's patients compared with the UK population. J Neurol Neurosurg Psychiatry 2007; 78: 1304-9.
8. Pezzoli G, Canesi M, Antonini A, et al. Hydrocarbon exposure and Parkinson's disease. Neurology 2000; 55: 667-73.
9. Clark LN, Haamer E, Mejia-Santana H, et al. Construction and validation of a Parkinson's disease mutation genotyping array for the Parkin gene. Mov Disord 2007; 22: 932-7.
10. Lesage S, Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 2009; 18: R48-59.
11. Farlow J, Pankratz ND, Wojcieszek J, Foroud T. Parkinson Disease Overview. In: Pagon RA, Adam MP, Ardinger HH, et al., Eds. GeneReviews(R). Seattle (WA): 1993.
12. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983; 219: 979-80.
13. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003; 39: 889-909.
14. Cohen G. Oxidative stress, mitochondrial respiration, and Parkinson's disease. Ann NY Acad Sci 2000; 899: 112-20.
15. Braak H, Rub U, Gai WP, Del Tredici K. Idiopathic Parkinson's disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J Neural Transm 2003; 110: 517-36.
16. Dickson DW, Braak H, Duda JE, et al. Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria. Lancet Neurol 2009; 8: 1150-7.
17. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
18. Peterson LJ, Flood PM. Oxidative stress and microglial cells in Parkinson's disease. Mediat Inflammation 2012; 2012: 401264.
19. Hwang O. Role of oxidative stress in Parkinson's disease. Exp Neurobiol 2013; 22: 11-7.
20. Zhou C, Huang Y, Przedborski S. Oxidative stress in Parkinson's disease: a mechanism of pathogenic and therapeutic significance. Ann NY Acad Sci 2008; 1147: 93-104.
21. Moore DJ, West AB, Dawson VL, Dawson TM. Molecular pathophysiology of Parkinson's disease. Annu Rev Neurosci 2005; 28: 57-87.
22. Golembiowska K, Dziubina A, Kowalska M, Kaminska K. Paradoxical effects of adenosine receptor ligands on hydroxyl radical generation by L-DOPA in the rat striatum. Pharmacol Rep 2008; 60: 319-30.
23. Cadet JL, Brannock C. Free radicals and the pathobiology of brain dopamine systems. Neurochem Int 1998; 32: 117-31.
24. Asanuma M, Miyazaki I, Ogawa N. Dopamine- or L-DOPAinduced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. Neurotox Res 2003; 5: 165-76.
25. Dickson DW. Linking selective vulnerability to cell death mechanisms in Parkinson's disease. Am J Pathol 2007; 170: 16-9.
26. Zeevalk GD, Razmpour R, Bernard LP. Glutathione and Parkinson's disease: is this the elephant in the room? Biomed Pharmacother 2008; 62: 236-49.
27. Bosco DA, Fowler DM, Zhang Q, et al. Elevated levels of oxidized cholesterol metabolites in Lewy body disease brains accelerate alpha-synuclein fibrilization. Nat Chem Biol 2006; 2: 249-53.
28. Nakabeppu Y, Tsuchimoto D, Yamaguchi H, Sakumi K. Oxidative damage in nucleic acids and Parkinson's disease. J Neurosci Res 2007; 85: 919-34.
29. Betarbet R, Sherer TB, Greenamyre JT. Animal models of Parkinson's disease. BioEssays 2002; 24: 308-18.
30. Sanyal J, Bandyopadhyay SK, Banerjee TK, et al. Plasma levels of lipid peroxides in patients with Parkinson's disease. Eur Rev Med Pharmacol Sci 2009; 13: 129-32.
31. Dexter DT, Carter CJ, Wells FR, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem 1989; 52: 381-9.
32. Yoritaka A, Hattori N, Uchida K, et al. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci USA 1996; 93: 2696-701.
33. Alam ZI, Daniel SE, Lees AJ, et al. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem 1997; 69: 1326-9.
34. Chung KK, Thomas B, Li X, et al. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science 2004; 304: 1328-31.
35. Shigenaga MK, Ames BN. Assays for 8-hydroxy-2'- deoxyguanosine: a biomarker of in vivo oxidative DNA damage. Free Radic Biol Med 1991; 10: 211-6.
36. Kraft AD, Harry GJ. Features of microglia and neuroinflammation relevant to environmental exposure and neurotoxicity. Int J Env Res Public Health 2011; 8: 2980-3018.
37. Bronstein DM, Perez-Otano I, Sun V, et al. Glia-dependent neurotoxicity and neuroprotection in mesencephalic cultures. Brain Res 1995; 704: 112-6.
38. Zhang W, Wang T, Pei Z, et al. Aggregated alpha-synuclein activates microglia: a process leading to disease progression in Parkinson's disease. FASEB J 2005; 19: 533-42.
39. Dehmer T, Lindenau J, Haid S, Dichgans J, Schulz JB. Deficiency of inducible nitric oxide synthase protects against MPTP toxicity in vivo. J Neurochem 2000; 74: 2213-6.
40. Factor SA, Sanchez-Ramos J, Weiner WJ. Trauma as an etiology of parkinsonism: a historical review of the concept. Mov Disord 1988; 3: 30-6.
41. Ling Z, Gayle DA, Ma SY, et al. In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain. Mov Disord 2002; 17: 116-24.
42. Block ML, Hong JS. Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem Soc Trans 2007; 35: 1127- 32.
43. Hunot S, Boissiere F, Faucheux B, et al. Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience 1996; 72: 355-63.
44. Choi DK, Pennathur S, Perier C, et al. Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice. J Neurosci 2005; 25: 6594-600.
45. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988; 38: 1285-91.
46. Hirsch EC, Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 2009; 8: 382-97.
47. Kim WG, Mohney RP, Wilson B, et al. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J Neurosci 2000; 20: 6309-16.
48. Gao HM, Hong JS. Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol 2008; 29: 357-65.
49. Arimoto T, Bing G. Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration. Neurobiol Dis 2003; 12: 35-45.
50. Kim SU, de Vellis J. Microglia in health and disease. J Neurosci Res 2005; 81: 302-13.
51. Henry CJ, Huang Y, Wynne AM, Godbout JP. Peripheral lipopolysaccharide (LPS) challenge promotes microglial hyperactivity in aged mice that is associated with exaggerated induction of both pro-inflammatory IL-1beta and anti-inflammatory IL-10 cytokines. Brain Behav Immunity 2009; 23: 309-17.
52. Teismann P. COX-2 in the neurodegenerative process of Parkinson's disease. BioFactors 2012; 38: 395-7.
53. Tsai SJ, Chao CY, Yin MC. Preventive and therapeutic effects of caffeic acid against inflammatory injury in striatum of MPTPtreated mice. Eur J Pharmacol 2011; 670: 441-7.
54. Lee JK, Tran T, Tansey MG. Neuroinflammation in Parkinson's disease. J Neuroimmune Pharmacol 2009; 4: 419-29.
55. De Lella Ezcurra AL, Chertoff M, Ferrari C, Graciarena M, Pitossi F. Chronic expression of low levels of tumor necrosis factor-alpha in the substantia nigra elicits progressive neurodegeneration, delayed motor symptoms and microglia/macrophage activation. Neurobiol Dis 2010; 37: 630-40.
56. Gordon R, Anantharam V, Kanthasamy AG, Kanthasamy A. Proteolytic activation of proapoptotic kinase protein kinase Cdelta by tumor necrosis factor alpha death receptor signaling in dopaminergic neurons during neuroinflammation. J Neuroinflammation 2012; 9: 82.
57. Orr CF, Rowe DB, Halliday GM. An inflammatory review of Parkinson's disease. Prog Neurobiol 2002; 68: 325-40.
58. Farooqui AA, Horrocks LA, Farooqui T. Modulation of inflammation in brain: a matter of fat. J Neurochem 2007; 101: 577-99.
59. Ransohoff RM, Perry VH. Microglial physiology: unique stimuli, specialized responses. Annu Rev Immunol 2009; 27: 119-45.
60. Reale M, Iarlori C, Thomas A, et al. Peripheral cytokines profile in Parkinson's disease. Brain Behav Immunity 2009; 23: 55-63.
61. Baba Y, Kuroiwa A, Uitti RJ, Wszolek ZK, Yamada T. Alterations of T-lymphocyte populations in Parkinson disease. Parkins Relat Disord 2005; 11: 493-8.
62. Stone DK, Reynolds AD, Mosley RL, Gendelman HE. Innate and adaptive immunity for the pathobiology of Parkinson's disease. Antioxid Redox Signal 2009; 11: 2151-66.
63. Tansey MG, Goldberg MS. Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiol Dis 2010; 37: 510-8.
64. Dipasquale B, Marini AM, Youle RJ. Apoptosis and DNA degradation induced by 1-methyl-4-phenylpyridinium in neurons. Biochem Biophys Res Commun 1991; 181: 1442-8.
65. Tompkins MM, Basgall EJ, Zamrini E, Hill WD. Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. Am J Pathol 1997; 150: 119-31.
66. Wullner U, Kornhuber J, Weller M, et al. Cell death and apoptosis regulating proteins in Parkinson's disease--a cautionary note. Acta Neuropathol 1999; 97: 408-12.
67. Banati RB, Daniel SE, Blunt SB. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease. Mov Disord 1998; 13: 221-7.
68. Tatton NA. Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp Neurol 2000; 166: 29-43.
69. Hartmann A, Hunot S, Michel PP, et al. Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci USA 2000; 97: 2875-80.
70. Hartmann A, Troadec JD, Hunot S, et al. Caspase-8 is an effector in apoptotic death of dopaminergic neurons in Parkinson's disease, but pathway inhibition results in neuronal necrosis. J Neurosci 2001; 21: 2247-55.
71. Mogi M, Togari A, Kondo T, et al. Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from parkinsonian brain. J Neural Transm 2000; 107: 335-41.
72. Viswanath V, Wu Y, Boonplueang R, et al. Caspase-9 activation results in downstream caspase-8 activation and bid cleavage in 1- methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease. J Neurosci 2001; 21: 9519-28.
73. Hartley A, Stone JM, Heron C, Cooper JM, Schapira AH. Complex I inhibitors induce dose-dependent apoptosis in PC12 cells: relevance to Parkinson's disease. J Neurochem 1994; 63: 1987-90.
74. Simunovic F, Yi M, Wang Y, et al. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson's disease pathology. Brain 2009; 132: 1795-809.
75. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004; 44: 601-7.
76. Ho CC, Rideout HJ, Ribe E, Troy CM, Dauer WT. The Parkinson disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegeneration. J Neurosci 2009; 29: 1011-6.
77. Zhu M, Li WW, Lu CZ. Histone Decacetylase Inhibitors Prevent Mitochondrial Fragmentation and Elicit Early Neuroprotection against MPP+. CNS Neurosci Therap 2014; 20: 308-16.
78. Wu L, Tian YY, Shi JP, et al. Inhibition of endoplasmic reticulum stress is involved in the neuroprotective effects of candesartan cilexitil in the rotenone rat model of Parkinson's disease. Neurosci Lett 2013; 548: 50-5.
79. Wu F, Wang Z, Gu JH, et al. p38(MAPK)/p53-Mediated Bax induction contributes to neurons degeneration in rotenone-induced cellular and rat models of Parkinson's disease. Neurochem Int 2013; 63: 133-40.
80. Ghosh A, Saminathan H, Kanthasamy A, et al. The peptidyl-prolyl isomerase Pin1 up-regulation and proapoptotic function in dopaminergic neurons: relevance to the pathogenesis of Parkinson disease. J Biol Chem 2013; 288: 21955-71.
81. Bernstein AI, O'Malley KL. MPP+-induces PUMA- and p53- dependent, but ATF3-independent cell death. Toxicol Lett 2013; 219: 93-8.
82. Ghavami S, Shojaei S, Yeganeh B, et al. Autophagy and apoptosis dysfunction in neurodegenerative disorders. Prog Neurobiol 2014; 112: 24-49.
83. Anglade P, Vyas S, Javoy-Agid F, et al. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol 1997; 12: 25-31.
84. Hara T, Nakamura K, Matsui M, et al. Suppression of basal autophagy in neural cells causes neurodegenerative disease in mice. Nature 2006; 441: 885-9.
85. Alegre-Abarrategui J, Christian H, Lufino MM, et al. LRRK2 regulates autophagic activity and localizes to specific membrane microdomains in a novel human genomic reporter cellular model. Hum Mol Genet 2009; 18: 4022-34.
86. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with lewy bodies. Proc Natl Acad Sci USA 1998; 95: 6469-73.
87. Recchia A, Debetto P, Negro A, et al. Alpha-synuclein and Parkinson's disease. FASEB J 2004; 18: 617-26.
88. Betarbet R, Sherer TB, Greenamyre JT. Ubiquitin-proteasome system and Parkinson's diseases. Exp Neurol 2005; 191 Suppl 1: S17-27.
89. Cuervo AM, Stefanis L, Fredenburg R, Lansbury PT, Sulzer D. Impaired degradation of mutant alpha-synuclein by chaperonemediated autophagy. Science 2004; 305: 1292-5.
90. Stefanis L. Caspase-dependent and -independent neuronal death: two distinct pathways to neuronal injury. Neuroscientist 2005; 11: 50-62.
91. Sohal RS, Ku HH, Agarwal S, Forster MJ, Lal H. Oxidative damage, mitochondrial oxidant generation and antioxidant defenses during aging and in response to food restriction in the mouse. Mech Ageing Dev 1994; 74: 121-33.
92. Bossy B, Perkins G, Bossy-Wetzel E. Clearing the brain's cobwebs: the role of autophagy in neuroprotection. Curr Neuropharmacol 2008; 6: 97-101.
93. Michiorri S, Gelmetti V, Giarda E, et al. The Parkinson-associated protein PINK1 interacts with Beclin1 and promotes autophagy. Cell Death Diff 2010; 17: 962-74.
94. Vogiatzi T, Xilouri M, Vekrellis K, Stefanis L. Wild type alphasynuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J Biol Chem 2008; 283: 23542- 56.
95. Pan T, Kondo S, Zhu W, et al. Neuroprotection of rapamycin in lactacystin-induced neurodegeneration via autophagy enhancement. Neurobiol Dis 2008; 32: 16-25.
96. Beale AM, Higgins RJ, Work TM, et al. MPTP-induced Parkinsonlike disease in sheep: clinical and pathologic findings. J Environ Pathol Toxicol Oncol 1989; 9: 417-28.
97. Quigney DJ, Gorman AM, Samali A. Heat shock protects PC12 cells against MPP+ toxicity. Brain Res 2003; 993: 133-9.
98. Ambrosi G, Ghezzi C, Sepe S, et al. Bioenergetic and proteolytic defects in fibroblasts from patients with sporadic Parkinson's disease. Biochim Biophys Acta 2014; 1842: 1385-94.
99. Nagai Y, Ueno S, Saeki Y, et al. Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease. Neurology 1996; 46: 791-5.
100. Barbanti P, Fabbrini G, Ricci A, et al. Increased expression of dopamine receptors on lymphocytes in Parkinson's disease. Mov Disord 1999; 14: 764-71.
101. Jankovic J, Chen S, Le WD. The role of Nurr1 in the development of dopaminergic neurons and Parkinson's disease. Prog Neurobiol 2005; 77: 128-38.
102. Caronti B, Antonini G, Calderaro C, et al. Dopamine transporter immunoreactivity in peripheral blood lymphocytes in Parkinson's disease. J Neural Transm 2001; 108: 803-7.
103. Caronti B, Tanda G, Colosimo C, et al. Reduced dopamine in peripheral blood lymphocytes in Parkinson's disease. Neuroreport 1999; 10: 2907-10.
104. Buttarelli FR, Capriotti G, Pellicano C, et al. Central and peripheral dopamine transporter reduction in Parkinson's disease. Neurol Res 2009; 31: 687-91.
105. Petrozzi L, Lucetti C, Gambaccini G, et al. Cytogenetic analysis oxidative damage in lymphocytes of Parkinson's disease patients. Neurol Sci 2001; 22: 83-4.
106. Migliore L, Petrozzi L, Lucetti C, et al. Oxidative damage and cytogenetic analysis in leukocytes of Parkinson's disease patients. Neurology 2002; 58: 1809-15.
107. Prigione A, Begni B, Galbussera A, et al. Oxidative stress in peripheral blood mononuclear cells from patients with Parkinson's disease: negative correlation with levodopa dosage. Neurobiol Dis 2006; 23: 36-43.
108. Migliore L, Coppede F. Genetic and environmental factors in cancer and neurodegenerative diseases. Mutat Res 2002; 512: 135- 53.
109. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999; 56: 33-9.
110. Bongioanni P, Mondino C, Borgna M, et al. T-lymphocyte immuno-interferon binding in parkinsonian patients. J Neural Transm 1997; 104: 199-207.
111. Dobbs RJ, Charlett A, Purkiss AG, et al. Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol Scand 1999; 100: 34-41.
112. Hisanaga K, Asagi M, Itoyama Y, Iwasaki Y. Increase in peripheral CD4 bright+ CD8 dull+ T cells in Parkinson disease. Arch Neurol 2001; 58: 1580-3.
113. Stypula G, Kunert-Radek J, Stepien H, Zylinska K, Pawlikowski M. Evaluation of interleukins, ACTH, cortisol and prolactin concentrations in the blood of patients with parkinson's disease. Neuroimmunomodulation 1996; 3: 131-4.
114. Muftuoglu M, Elibol B, Dalmizrak O, et al. Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations. Mov Disord 2004; 19: 544-8.
115. Blandini F, Sinforiani E, Pacchetti C, et al. Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease. Neurology 2006; 66: 529-34.
116. Kim S, Jeon BS, Heo C, et al. Alpha-synuclein induces apoptosis by altered expression in human peripheral lymphocyte in Parkinson's disease. FASEB J 2004; 18: 1615-7.
117. Brunner T, Wasem C, Torgler R, et al. Fas (CD95/Apo-1) ligand regulation in T cell homeostasis, cell-mediated cytotoxicity and immune pathology. Semin Immunol 2003; 15: 167-76.
118. Calopa M, Bas J, Callen A, Mestre M. Apoptosis of peripheral blood lymphocytes in Parkinson patients. Neurobiol Dis 2010; 38: 1-7.
119. Hartmann A, Michel PP, Troadec JD, et al. Is Bax a mitochondrial mediator in apoptotic death of dopaminergic neurons in Parkinson's disease? J Neurochem 2001; 76: 1785-93.
120. Mochizuki H, Goto K, Mori H, Mizuno Y. Histochemical detection of apoptosis in Parkinson's disease. J Neurol Sci 1996; 137: 120-3.
121. Blandini F, Cosentino M, Mangiagalli A, et al. Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson's disease. The effect of dopaminergic treatment. J Neural Transm 2004; 111: 1017-30.
122. Robertson JD, Orrenius S. Molecular mechanisms of apoptosis induced by cytotoxic chemicals. Crit Rev Toxicol 2000; 30: 609- 27.
123. Hong SJ, Dawson TM, Dawson VL. Nuclear and mitochondrial conversations in cell death: PARP-1 and AIF signaling. Trends Pharmacol Sci 2004; 25: 259-64.
124. Donovan M, Cotter TG. Control of mitochondrial integrity by Bcl- 2 family members and caspase-independent cell death. Biochim Biophys Acta 2004; 1644: 133-47.
125. Bidere N, Senik A. Caspase-independent apoptotic pathways in T lymphocytes: a minireview. Apoptosis 2001; 6: 371-5.
126. Tacconi S, Perri R, Balestrieri E, et al. Increased caspase activation in peripheral blood mononuclear cells of patients with Alzheimer's disease. Exp Neurol 2004; 190: 254-62.
127. Stocchi F, Olanow CW. Obstacles to the development of a neuroprotective therapy for Parkinson's disease. Mov Disord 2013; 28: 3-7.
128. Lohle M, Reichmann H. Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough. J Neurol Sci 2010; 289: 104-14.